Publications by authors named "Thomas Kipps"

Claim this Profile
A
Addition of Ianalumab (VAY736) to Ibrutinib in Patients with Chronic Lymphocytic Leukemia on Ibrutinib Therapy: Results from a Phase Ib Study.
Kerry A Rogers, Pearlly Yan, Ian W Flinn, Deborah M Stephens, Thomas J Kipps

Clin Cancer Res· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Retreatment with venetoclax and rituximab following disease progression while off therapy in patients with chronic lymphocytic leukemia.
Danielle M Brander, Andrew W Roberts, Thomas J Kipps, Shuo Ma, Mary Ann Anderson

Hemasphere· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Final analysis of the RESONATE-2 study: up to 10 years of follow-up of first-line ibrutinib treatment for CLL/SLL.
Jan A Burger, Paul M Barr, Tadeusz Robak, Carolyn Owen, Alessandra Tedeschi, Thomas J Kipps

Blood· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
SF3B1 mutation accelerates the development of CLL via activation of the mTOR pathway.
Bo Zhang, Prajish Iyer, Meiling Jin, Elisa Ten Hacken, Zachary J Cartun, Thomas J Kipps

JCI Insight· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Venetoclax Consolidation After Bruton Tyrosine Kinase Inhibitor Treatment for Patients With Chronic Lymphocytic Leukemia.
Benjamin Heyman, Michael Choi, Thomas J Kipps

EJHaem· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting PRDX1 impairs acute myeloid leukemic blasts and stem cells by disrupting redox homeostasis.
Zhenghao Li, Guangci Liu, Ziren Chen, Keming Li, Zhe Yu, Thomas J Kipps

Cell Death Dis· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
W
Wnt5a induces ROR1 dependent NF-κB activation to enhance MMP-9 expression and invasiveness in chronic lymphocytic leukemia.
Md Kamrul Hasan, George F Widhopf Ii, Emanuela M Ghia, Thomas J Kipps

Leukemia· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparative analysis of patients' characteristics, treatment, and survival outcomes in CLL from China and the United States.
Yuting Yan, Yin Liu, Tonglu Qiu, Fan Yang, Jiamei Liu, Thomas J Kipps

Oncologist· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The MURANO study: final analysis and retreatment/crossover substudy results of VenR for patients with relapsed/refractory CLL.
Arnon P Kater, Rosemary Harrup, Thomas J Kipps, Barbara Eichhorst, Carolyn J Owen

Blood· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The mutational landscape and functional effects of noncoding ultraconserved elements in human cancers.
Recep Bayraktar, Yitao Tang, Mihnea P Dragomir, Cristina Ivan, Xinxin Peng, Thomas J Kipps

Sci Adv· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting ROR2 homooligomerization disrupts ROR2-dependent signaling and suppresses stem-like cell properties of human breast adenocarcinoma.
Feng Leng, Jiajia Huang, Liufeng Wu, Jianchao Zhang, Xinxin Lin, Thomas J Kipps

iScience· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mutation in Bruton Tyrosine Kinase (BTK) A428D confers resistance To BTK-degrader therapy in chronic lymphocytic leukemia.
Richard L Wong, Michael Y Choi, Huan-You Wang, Thomas J Kipps

Leukemia· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Variant Transcript of ROR1 ENST00000545203 Does Not Encode ROR1 Protein.
Jie Xian, Navyaa Sinha, Christina Girgis, Christopher S Oh, Matthew R Cring, Thomas J Kipps

Biomedicines· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Aberrant spliceosome activity via elevated intron retention and upregulation and phosphorylation of SF3B1 in chronic lymphocytic leukemia.
Manoj Kumar Kashyap, Hiren Karathia, Deepak Kumar, Roberto Vera Alvarez, Jose Vicente Forero-Forero, Thomas J Kipps

Mol Ther Nucleic Acids· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology.
William G Wierda, Jennifer Brown, Jeremy S Abramson, Farrukh Awan, Syed F Bilgrami, Thomas J Kipps

J Natl Compr Canc Netw· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction: a phase 1b study of zilovertamab in combination with paclitaxel for locally advanced/unresectable or metastatic HER2-negative breast cancer.
Rebecca A Shatsky, Hemali Batra-Sharma, Teresa Helsten, Richard B Schwab, Emily I Pittman, Thomas J Kipps

Breast Cancer Res· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase 1b study of zilovertamab in combination with paclitaxel for locally advanced/unresectable or metastatic Her2-negative breast cancer.
Rebecca A Shatsky, Hemali Batra-Sharma, Teresa Helsten, Richard B Schwab, Emily I Pittman, Thomas J Kipps

Breast Cancer Res· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A + AVD for Treatment of Hodgkin Lymphoma Variant of Richter's Transformation.
Benjamin Heyman, Michael Choi, Thomas J Kipps

Case Rep Hematol· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Expression signature of human endogenous retroviruses in chronic lymphocytic leukemia.
Alessandro La Ferlita, Giovanni Nigita, Liudmyla Tsyba, Alexey Palamarchuk, Salvatore Alaimo, Thomas Kipps

Proc Natl Acad Sci U S A· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immune restoration with ibrutinib plus venetoclax in first-line chronic lymphocytic leukemia: the phase 2 CAPTIVATE study.
Carol Moreno, Isabelle G Solman, Constantine S Tam, Andrew Grigg, Lydia Scarfò, Thomas J Kipps

Blood Adv· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Challenging the Value of Minimal Residual Disease in Predicting Outcome of Patients With Chronic Lymphocytic Leukemia.
Thomas J Kipps

J Clin Oncol· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Outcomes in Patients with High-Risk Features after Fixed-Duration Ibrutinib plus Venetoclax: Phase II CAPTIVATE Study in First-Line Chronic Lymphocytic Leukemia.
John N Allan, Ian W Flinn, Tanya Siddiqi, Paolo Ghia, Constantine S Tam, Thomas J Kipps

Clin Cancer Res· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Association of baseline ROR1 and ROR2 gene expression with clinical outcomes in the I-SPY2 neoadjuvant breast cancer trial.
Barbara A Parker, Rebecca A Shatsky, Richard B Schwab, Anne M Wallace, , Thomas J Kipps

Breast Cancer Res Treat· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of cortactin in cancer progression on Wnt5a/ROR1 signaling pathway.
Kamrul Hasan, Thomas J Kipps

Oncotarget· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Characteristics and Clinical Outcomes of Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Receiving Ibrutinib for ≥5 Years in the RESONATE-2 Study.
Jennifer A Woyach, Paul M Barr, Thomas J Kipps, Jacqueline C Barrientos, Inhye E Ahn

Cancers (Basel)· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis